

ASX Release

HC Berlin Pharma Update

PERTH, AUSTRALIA – 1 May 2018: SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, provides an update to the matter with HC Berlin Pharma.

Following the ASX announcement of 29 March 2018 in which SUDA's Executive Chairman, Stephen Carter, advised the market that SUDA maintained the ability for further discussions with the Receiver of HC Berlin Pharma, SUDA wishes to confirm that the Receiver has indicated to the Board that he would be prepared to meet to discuss whether an outcome satisfactory to both parties can be agreed.

Accordingly, Mr Carter and Mr Michael Stewart intend to fly to Germany next week to undertake those discussions.

SUDA will provide a further update following those discussions taking place.



Further information:

STEPHEN CARTER

EXECUTIVE CHAIRMAN

SUDA Pharmaceuticals Ltd

Tel: +61 8 6142 555

sjcarter@sudapharma.com

NOTES TO EDITORS:

About SUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. SUDA has submitted a Marketing Authorisation Application to the Australian Therapeutic Goods Administration for ArTiMist®, its novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction, PAH, epileptic seizures and pre-procedural anxiety. For more information, visit www.sudapharma.com